Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine rich repeat containing 34 pseudogene 1 (LRRC34P1) is classified as a *pseudogene*, meaning it is a genomic locus that resembles a protein-coding gene (in this case, related to the LRRC34 gene) but is generally considered non-functional at the protein level[1][6]. Pseudogenes are sometimes transcribed into RNA, and some have demonstrated regulatory roles such as acting as competing endogenous RNAs (ceRNAs) or generating noncoding RNAs that affect expression of protein-coding genes[2][5][6]. However, there is **no evidence that LRRC34P1 has a defined biological function, participates in disease, serves as a drug target, or acts as a biomarker** in any clinical or research setting to date[1]. It inherits its name from sequence similarity to the protein-coding gene LRRC34, which is involved in stem cell regulation and differentiation[3], but LRRC34P1 itself is noncoding. No data support its classification as a **therapeutic target** or suggest clinical relevance for diagnostics, safety, or drug development[1]. The pseudogene does not encode a functional protein nor does it have catalogued regulatory or disease-associated roles. **Note:** - The entry is correct (the gene exists as a NCBI and HGNC entry as a pseudogene) but is **not a valid drug target** or receptor per canonical definitions[1][6]. - No meaningful aliases or alternative names are reported beyond its standard nomenclature and database identifiers[1].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leucine rich repeat containing 34 pseudogene 1 (LRRC34P1).